SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Gang Huang, Yuan Yang, Feng Shen, Ze-ya Pan, Si-yuan Fu, Wan Yee Lau, Wei-ping Zhou, Meng-chao Wu, Early Viral Suppression Predicts Good Postoperative Survivals in Patients with Hepatocellular Carcinoma with a High Baseline HBV-DNA Load, Annals of Surgical Oncology, 2013, 20, 5, 1482

    CrossRef

  2. 2
    Yuan Yang, Li Jin, Ying-Li He, Ke Wang, Xiao-Hua Ma, Jing Wang, Zhi Yan, Yu-Ling Feng, Yong-Qin Li, Tian-Yan Chen, Hong-Li Liu, Ying-Ren Zhao, Hepatitis B virus infection in clustering of infection in families with unfavorable prognoses in northwest China, Journal of Medical Virology, 2013, 85, 11
  3. You have free access to this content3
    Yorihisa Urata, Shoji Kubo, Shigekazu Takemura, Takahiro Uenishi, Shintaro Kodai, Hiroji Shinkawa, Masayuki Sakae, Kazuhisa Kaneda, Kazunori Ohata, Akinori Nozawa, Shigefumi Suehiro, Effects of antiviral therapy on long-term outcome after liver resection for hepatitis B virus-related hepatocellular carcinoma, Journal of Hepato-Biliary-Pancreatic Sciences, 2012, 19, 6
  4. 4
    Jin-Yong Zhou, Le Zhang, Lei Li, Guang-Yu Gu, Yi-Hua Zhou, Jun-Hao Chen, High hepatitis B virus load is associated with hepatocellular carcinomas development in Chinese chronic hepatitis B patients: a case control study, Virology Journal, 2012, 9, 1, 16

    CrossRef

  5. 5
    T. Yang, J.-H. Lu, J. Zhai, C. Lin, G.-S. Yang, R.-H. Zhao, F. Shen, M.-C. Wu, High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: A prospective cohort study, European Journal of Surgical Oncology (EJSO), 2012, 38, 8, 683

    CrossRef

  6. 6
    Sumalee Siriaunkgul, Utaiwan Utaipat, Supaporn Suwiwat, Jongkolnee Settakorn, Kornkanok Sukpan, Jatupol Srisomboon, Surapan Khunamornpong, Prognostic Value of HPV18 DNA Viral Load in Patients with Early-Stage Neuroendocrine Carcinoma of the Uterine Cervix, Asian Pacific Journal of Cancer Prevention, 2012, 13, 7, 3281

    CrossRef

  7. 7
    Jing Xu, Li Liu, Hong Tang, Antiviral therapy for hepatitis B virus-associated hepatocellular carcinoma: Potential to reduce the tumor recurrence rates and/or improve overall survival, Medical Hypotheses, 2011, 76, 3, 457

    CrossRef

  8. 8
    Beom Kyung Kim, Kwang-Hyub Han, Sang Hoon Ahn, Prevention of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Infection, Oncology, 2011, 81, s1, 41

    CrossRef

  9. 9
    Maria Stella De Mitri, Romina Cassini, Mauro Bernardi, Hepatitis B virus-related hepatocarcinogenesis: Molecular oncogenic potential of clear or occult infections, European Journal of Cancer, 2010, 46, 12, 2178

    CrossRef

  10. You have free access to this content10
    Ho Jung An, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Se Hyun Cho, Seung Kew Yoon, June Yeol Han, Keun Ho Lee, Dong Goo Kim, Eun Sun Jung, Sustained low hepatitis B viral load predicts good outcome after curative resection in patients with hepatocellular carcinoma, Journal of Gastroenterology and Hepatology, 2010, 25, 12
  11. 11
    Adrian M. Di Bisceglie, Hepatitis B and hepatocellular carcinoma, Hepatology, 2009, 49, S5
  12. 12
    Chien-Jen Chen, Hwai-I Yang, Uchenna H. Iloeje, Hepatitis B virus DNA levels and outcomes in chronic hepatitis B, Hepatology, 2009, 49, S5
  13. 13
    Puneeta Tandon, Guadalupe Garcia-Tsao, Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies, Liver International, 2009, 29, 4
  14. 14
    Elizabeth Arnold, Yong Yuan, Uchenna Iloeje, Greg Cook, Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B, Applied Health Economics and Health Policy, 2008, 6, 4, 231

    CrossRef

  15. 15
    Yong Yuan, Uchenna Iloeje, Hong Li, Joel Hay, Guang B. Yao, Economic Implications of Entecavir Treatment in Suppressing Viral Replication in Chronic Hepatitis B (CHB) Patients in China from a Perspective of the Chinese Social Security Program, Value in Health, 2008, 11,
  16. 16
    Po-Lin Tseng, Ming-Hong Tai, Chao-Cheng Huang, Chih-Chi Wang, Jui-Wei Lin, Chao-Hung Hung, Chien-Hung Chen, Jing-Houng Wang, Sheng-Nan Lu, Chuan-Mo Lee, Chi-Sin Changchien, Tsung-Hui Hu, Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients, Journal of Surgical Oncology, 2008, 98, 5
  17. 17
    J. Yin, H. Zhang, C. Li, C. Gao, Y. He, Y. Zhai, P. Zhang, L. Xu, X. Tan, J. Chen, S. Cheng, S. Schaefer, G. Cao, Role of hepatitis B virus genotype mixture, subgenotypes C2 and B2 on hepatocellular carcinoma: compared with chronic hepatitis B and asymptomatic carrier state in the same area, Carcinogenesis, 2008, 29, 9, 1685

    CrossRef

  18. 18
    I-Chin Wu, Nan-Haw Chow, Pin-Nan Cheng, Wen-Chun Liu, Kung-Chia Young, Wei-Lun Chang, Chi-Yi Chen, Kuo-Chih Tseng, Ting-Tsung Chang, Characterization of viral kinetics in patients with hepatitis B e antigen-positive chronic hepatitis B, Journal of Medical Virology, 2007, 79, 6
  19. 19
    Hui-Chuan Sun, Wei Zhang, Lun-Xiu Qin, Bo-Heng Zhang, Qing-Hai Ye, Lu Wang, Ning Ren, Peng-Yuan Zhuang, Xiao-Dong Zhu, Jia Fan, Zhao-You Tang, Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma, Journal of Hepatology, 2007, 47, 5, 684

    CrossRef

  20. 20
    Ronnie T.P. Poon, Significance of viral status on prognosis after resection of hepatitis B virus related hepatocellular carcinoma, Journal of Hepatology, 2007, 47, 5, 630

    CrossRef

  21. 21
    Andrés Ruiz-Sancho, Julie Sheldon, Vincent Soriano, Telbivudine: a new option for the treatment of chronic hepatitis B, Expert Opinion on Biological Therapy, 2007, 7, 5, 751

    CrossRef

  22. 22
    T.-K. CHEUNG, C.-L. LAI, B. C.-Y. WONG, J. FUNG, M.-F. YUEN, Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in Hong Kong, Alimentary Pharmacology & Therapeutics, 2006, 24, 4
  23. 23
    Jean-Pierre Allain, Epidemiology of Hepatitis B virus and genotype, Journal of Clinical Virology, 2006, 36, S12

    CrossRef

  24. 24
    G. BALTAYIANNIS, K. KATSANOS, P. KARAYIANNIS, E. V. TSIANOS, Interferon-α therapy in HBeAg-negative chronic hepatitis B: a long-term prospective study from north-western Greece, Alimentary Pharmacology & Therapeutics, 2006, 24, 3
  25. 25
    Mitsuhiko Moriyama, Hiroshi Matsumura, Jiro Shioda, Hiroshi Aoki, Hitomi Nakamura, Yasuo Arakawa, Kazushige Nirei, Hiroaki Yamagami, Miki Kaneko, Naohide Tanaka, Yasuyuki Arakawa, Measurement of Human Intercellular Adhesion Molecule 1 in the Blood Is Useful for Predicting the Occurrence of Hepatocellular Carcinomas from Chronic Hepatitis C and Liver Cirrhosis, Intervirology, 2006, 49, 6, 327

    CrossRef

  26. 26
    Gang Chen, Wenyao Lin, Fumin Shen, Uchenna H. Iloeje, W. Thomas London, Alison A. Evans, Past HBV Viral Load as Predictor of Mortality and Morbidity from HCC and Chronic Liver Disease in a Prospective Study, The American Journal of Gastroenterology, 2006, 101, 8, 1797

    CrossRef

  27. 27
    Ching-Lung Lai, Nancy Leung, Eng-Kiong Teo, Myron Tong, Florence Wong, Hie-Won Hann, Steven Han, Thierry Poynard, Maureen Myers, George Chao, Deborah Lloyd, Nathaniel A. Brown, A 1-Year Trial of Telbivudine, Lamivudine, and the Combination in Patients With Hepatitis B e Antigen—Positive Chronic Hepatitis B, Gastroenterology, 2005, 129, 2, 528

    CrossRef

  28. 28
    Sabina Mahmood, Gouichi Niiyama, Ayumi Kamei, Akiyoshi Izumi, Keiichi Nakata, Hideji Ikeda, Mitsuhiko Suehiro, Miwa Kawanaka, Kazumi Togawa, Gotaro Yamada, Influence of viral load and genotype in the progression of Hepatitis B-associated liver cirrhosis to hepatocellular carcinoma, Liver International, 2005, 25, 2
  29. 29
    Steven-Huy B Han, Telbivudine: a new nucleoside analogue for the treatment of chronic hepatitis B, Expert Opinion on Investigational Drugs, 2005, 14, 4, 511

    CrossRef

  30. 30
    M.A. Hayat, Molecular Genetics, Liver Carcinoma, and Pancreatic Carcinoma, 2005,

    CrossRef

  31. 31
    Ching-Lung Lai, Seng Gee Lim, Nathaniel A. Brown, Xiao-Jian Zhou, Deborah M. Lloyd, Yin-Mei Lee, Man-Fung Yuen, George C. Chao, Maureen W. Myers, A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection, Hepatology, 2004, 40, 3
  32. 32
    KAZUYUKI OHATA, KEISUKE HAMASAKI, KAN TORIYAMA, HIROKI ISHIKAWA, KAZUHIKO NAKAO, KATSUMI EGUCHI, High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection, Journal of Gastroenterology and Hepatology, 2004, 19, 6
  33. 33
    R. Kannangai, E. Molmenti, L. Arrazola, A. Klein, M. Choti, D. L. Thomas, M. Torbenson, Occult hepatitis B viral DNA in liver carcinomas from a region with a low prevalence of chronic hepatitis B infection, Journal of Viral Hepatitis, 2004, 11, 4
  34. 34
    Henry Lik-Yuen Chan, Albert Ka-Keung Chui, Wan-Yee Lau, Francis Ka-Leung Chan, Alex Yui Hui, Araga Ramesha Nitin Rao, John Wong, Eric Chun-Hung Lai, Joseph Jao-Yiu Sung, Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monoprophylaxis, Clinical Transplantation, 2004, 18, 3
  35. 35
    Tim Shaw, Scott Bowden, Stephen Locarnini, Chemotherapy for hepatitis B: New treatment options necessitate reappraisal of traditional endpoints, Gastroenterology, 2002, 123, 6, 2135

    CrossRef